Cargando…

Gradient changes in bioprosthetic valve thrombosis: duration of anticoagulation and strategies to improve detection

OBJECTIVE: Bioprosthetic valve thrombosis (BPVT) is increasingly recognised as a major cause of prosthetic dysfunction in the first years postimplantation. How early abnormal gradients can be detected prior to diagnosis and how fast they normalise with anticoagulant therapy is unknown. We set forth...

Descripción completa

Detalles Bibliográficos
Autores principales: Naser, Jwan A, Petrescu, Ioana, Ionescu, Filip, Nkomo, Vuyisile T, Pislaru, Cristina, Schaff, Hartzell V, Pellikka, Patricia A, Connolly, Heidi M, Egbe, Alexander C, Pislaru, Sorin V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149431/
https://www.ncbi.nlm.nih.gov/pubmed/34031215
http://dx.doi.org/10.1136/openhrt-2021-001608
_version_ 1783697959817314304
author Naser, Jwan A
Petrescu, Ioana
Ionescu, Filip
Nkomo, Vuyisile T
Pislaru, Cristina
Schaff, Hartzell V
Pellikka, Patricia A
Connolly, Heidi M
Egbe, Alexander C
Pislaru, Sorin V
author_facet Naser, Jwan A
Petrescu, Ioana
Ionescu, Filip
Nkomo, Vuyisile T
Pislaru, Cristina
Schaff, Hartzell V
Pellikka, Patricia A
Connolly, Heidi M
Egbe, Alexander C
Pislaru, Sorin V
author_sort Naser, Jwan A
collection PubMed
description OBJECTIVE: Bioprosthetic valve thrombosis (BPVT) is increasingly recognised as a major cause of prosthetic dysfunction in the first years postimplantation. How early abnormal gradients can be detected prior to diagnosis and how fast they normalise with anticoagulant therapy is unknown. We set forth to (1) evaluate patterns of increase in gradients prior to BPVT diagnosis and (2) characterise time-course of response to anticoagulation. METHODS: Patients treated with warfarin for BPVT (1999–2019) with clinically significant reduction of mean gradients (≥25%) were identified retrospectively. Recovery was defined as gradient decrease ≥50%, to postimplantation or to normal-range gradients per position, model and size. Time-to-BPVT (implantation—BPVT diagnosis), potential diagnostic delay (first abnormal gradient by position, model and size—BPVT diagnosis) and time-to-recovery (BPVT diagnosis—complete resolution) were recorded. RESULTS: 77 patients were identified; 32 (42%) aortic (23 surgical—12 porcine, 11 pericardial; 9 transcatheter); 24 (31%) mitral; 21 (27%) tricuspid. Median time-to-BPVT was 24, 21 and 10 months, respectively. Potential diagnostic delay was median 21 months for aortic, 4 months for mitral, but 0 for tricuspid. Recovery was significantly faster in mitral than aortic (median 2.5 vs 4.8 months, p=0.038) and tricuspid (median 5.9 months, p=0.025) positions. Porcine aortic valves responded faster than pericardial aortic valves (median 2.9 vs 20.3 months, p=0.004). CONCLUSION: Gradients start to increase months before the clinical BPVT diagnosis. Recovery is faster in mitral and surgical aortic porcine valves; a longer warfarin trial seems indicated in tricuspid and surgical aortic pericardial valves.
format Online
Article
Text
id pubmed-8149431
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-81494312021-06-09 Gradient changes in bioprosthetic valve thrombosis: duration of anticoagulation and strategies to improve detection Naser, Jwan A Petrescu, Ioana Ionescu, Filip Nkomo, Vuyisile T Pislaru, Cristina Schaff, Hartzell V Pellikka, Patricia A Connolly, Heidi M Egbe, Alexander C Pislaru, Sorin V Open Heart Valvular Heart Disease OBJECTIVE: Bioprosthetic valve thrombosis (BPVT) is increasingly recognised as a major cause of prosthetic dysfunction in the first years postimplantation. How early abnormal gradients can be detected prior to diagnosis and how fast they normalise with anticoagulant therapy is unknown. We set forth to (1) evaluate patterns of increase in gradients prior to BPVT diagnosis and (2) characterise time-course of response to anticoagulation. METHODS: Patients treated with warfarin for BPVT (1999–2019) with clinically significant reduction of mean gradients (≥25%) were identified retrospectively. Recovery was defined as gradient decrease ≥50%, to postimplantation or to normal-range gradients per position, model and size. Time-to-BPVT (implantation—BPVT diagnosis), potential diagnostic delay (first abnormal gradient by position, model and size—BPVT diagnosis) and time-to-recovery (BPVT diagnosis—complete resolution) were recorded. RESULTS: 77 patients were identified; 32 (42%) aortic (23 surgical—12 porcine, 11 pericardial; 9 transcatheter); 24 (31%) mitral; 21 (27%) tricuspid. Median time-to-BPVT was 24, 21 and 10 months, respectively. Potential diagnostic delay was median 21 months for aortic, 4 months for mitral, but 0 for tricuspid. Recovery was significantly faster in mitral than aortic (median 2.5 vs 4.8 months, p=0.038) and tricuspid (median 5.9 months, p=0.025) positions. Porcine aortic valves responded faster than pericardial aortic valves (median 2.9 vs 20.3 months, p=0.004). CONCLUSION: Gradients start to increase months before the clinical BPVT diagnosis. Recovery is faster in mitral and surgical aortic porcine valves; a longer warfarin trial seems indicated in tricuspid and surgical aortic pericardial valves. BMJ Publishing Group 2021-05-24 /pmc/articles/PMC8149431/ /pubmed/34031215 http://dx.doi.org/10.1136/openhrt-2021-001608 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Valvular Heart Disease
Naser, Jwan A
Petrescu, Ioana
Ionescu, Filip
Nkomo, Vuyisile T
Pislaru, Cristina
Schaff, Hartzell V
Pellikka, Patricia A
Connolly, Heidi M
Egbe, Alexander C
Pislaru, Sorin V
Gradient changes in bioprosthetic valve thrombosis: duration of anticoagulation and strategies to improve detection
title Gradient changes in bioprosthetic valve thrombosis: duration of anticoagulation and strategies to improve detection
title_full Gradient changes in bioprosthetic valve thrombosis: duration of anticoagulation and strategies to improve detection
title_fullStr Gradient changes in bioprosthetic valve thrombosis: duration of anticoagulation and strategies to improve detection
title_full_unstemmed Gradient changes in bioprosthetic valve thrombosis: duration of anticoagulation and strategies to improve detection
title_short Gradient changes in bioprosthetic valve thrombosis: duration of anticoagulation and strategies to improve detection
title_sort gradient changes in bioprosthetic valve thrombosis: duration of anticoagulation and strategies to improve detection
topic Valvular Heart Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149431/
https://www.ncbi.nlm.nih.gov/pubmed/34031215
http://dx.doi.org/10.1136/openhrt-2021-001608
work_keys_str_mv AT naserjwana gradientchangesinbioprostheticvalvethrombosisdurationofanticoagulationandstrategiestoimprovedetection
AT petrescuioana gradientchangesinbioprostheticvalvethrombosisdurationofanticoagulationandstrategiestoimprovedetection
AT ionescufilip gradientchangesinbioprostheticvalvethrombosisdurationofanticoagulationandstrategiestoimprovedetection
AT nkomovuyisilet gradientchangesinbioprostheticvalvethrombosisdurationofanticoagulationandstrategiestoimprovedetection
AT pislarucristina gradientchangesinbioprostheticvalvethrombosisdurationofanticoagulationandstrategiestoimprovedetection
AT schaffhartzellv gradientchangesinbioprostheticvalvethrombosisdurationofanticoagulationandstrategiestoimprovedetection
AT pellikkapatriciaa gradientchangesinbioprostheticvalvethrombosisdurationofanticoagulationandstrategiestoimprovedetection
AT connollyheidim gradientchangesinbioprostheticvalvethrombosisdurationofanticoagulationandstrategiestoimprovedetection
AT egbealexanderc gradientchangesinbioprostheticvalvethrombosisdurationofanticoagulationandstrategiestoimprovedetection
AT pislarusorinv gradientchangesinbioprostheticvalvethrombosisdurationofanticoagulationandstrategiestoimprovedetection